Publique en esta revista
Información de la revista
Vol. 2. Núm. S2.
IV Simposio de Artritis Reumatoide
Páginas S52-S59 (Marzo 2006)
Compartir
Compartir
Descargar PDF
Más opciones de artículo
Vol. 2. Núm. S2.
IV Simposio de Artritis Reumatoide
Páginas S52-S59 (Marzo 2006)
Artritis reumatoide: aspectos prácticos
Acceso a texto completo
III Actualización del Consenso de la Sociedad Española de Reumatología sobre terapia biológica en la artritis reumatoide
Visitas
...
Vicente Rodríguez-Valverde??, Rafael Cáliz Cáliz, José M. Álvaro-Gracia Álvaro, José L. Marenco de la Fuente, Juan Mulero Mendoza, Jesús Tornero Molina, J.L. Andréu Sánchez, F.J. Ballina García, E. Batlle Gualda, J.D. Cañete Crespillo, J. Carbonell Abelló, L. Carreño Pérez, M. Figueroa Pedrosa, J. Gómez-Reino Carnota, T. González García, A. Laffon Roca, E. Martín Mola, E. Pascual Gómez, R. Sanmartí Sala, J.M. Salazar Vallinas, J. Valverde García
Información del artículo
El Texto completo está disponible en PDF
Bibliografía
[1.]
L. Carmona, J. Ballina, R. Gabriel, A. Laffon.
The burden of musculoskeletal diseases in the general population of Spain: results from a national survey.
Ann Rheum Dis, 60 (2001), pp. 1040-1045
[2.]
L.R. Lard, H. Visser, I. Speyer, I.E. Van der Horst-Bruinsman, A.H. Zwinderman, F.C. Breedveld, et al.
Early versus delayed treatment in patients with recent-onset rheumatoid arthritis: comparison of two cohorts who received different treatment strategies.
Am J Med, 111 (2001), pp. 446-451
[3.]
V.P.K. Nell, K.P. Machold, G. Eberl, T.A. Stamm, M. Uffmann, J.S. Smolen.
Benefit of very early referral and very early therapy with disease-modifying anti-rheumatic drugs in patients with very early rheumatoid arthritis.
Rheumatolology, 43 (2004), pp. 906-914
[4.]
V. Rodríguez-Valverde, J.M. Álvaro-Gracia, J.L. Andreu, E. Batlle, J.L. Tornero.
Segunda actualización del Consenso de la Sociedad Española de Reumatología sobre la Terapia Biológica en la Artritis Reumatoide.
Rev Esp Reumatol, 31 (2004), pp. 394-401
[5.]
M.E. Weinblatt, J.M. Kremer, A.D. Bankhurst, K.J. Bulpitt, R.M. Fleichsmann, R.I. Fox, et al.
A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate.
N Engl J Med, 340 (1999), pp. 253-259
[6.]
P.E. Lipsky, D.M. Van der Heijde, E.W. St Clair, D.E. Furst, F.C. Breedveld, J.R. Kalden, et al.
Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-tumor necrosis factor trial in rheumatoid arthritis with concomitant therapy study group.
N Engl J Med, 343 (2000), pp. 1594-1602
[7.]
M.E. Weinblatt, E.C. Keystone, D.E. Furst, L.W. Moreland, M.H. Weisman, Ch.A. Birbara, et al.
Adalimumab, a fully Human anti-tumor necrosis factor monoclonal antibody for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate. The ARMADA trial.
Arthritis Rheum, 48 (2003), pp. 35-45
[8.]
J.M. Bathon, R.W. Martin, R.M. Fleischman, J.R. Tesser, M.H. Schiff, E.C. Keystone, et al.
A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis.
N Engl J Med, 343 (2000), pp. 1586-1593
[9.]
E.W. St.Clair, D.M. Van der Heijde, J.S. Smolen, R.N. Maini, J.M. Bathon, P. Emery, et al.
Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized controlled trial.
Arthritis Rheum, 50 (2004), pp. 3432-3443
[10.]
F.C. Breedveld, M.H. Weisman, A.F. Kavanaugh, S.B. Cohen, K. Pavelka, R. Van Vollenhoven, The PREMIER study, et al.
A multicenter randomized double-blind clinical trial of combination therapy with adalimuumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment.
Arthritis Rheum, 54 (2004), pp. 26-37
[11.]
D. Van der Heijde, L. Klareskog, V. Rodriguez-Valverde, C. Codreanu, H. Bolosiu, J. Melo-Gomes, et al.
Comparison of etanercept and methotrexate, alone and combined, in the treatment of rheumatoid arthritis: two-year clinical and radiographic results from the TEMPO study, a double-blind, randomized trial.
Arthritis Rheum, 54 (2006), pp. 1063-1074
[12.]
J.R. Kalden, C. Antoni, J.M. Alvaro-Gracia, B. Combe, P. Emery, J.M. Kremer, et al.
Use of combination of leflunomide with biological agents in treatment of rheumatoid arthritis.
J Rheumatol, 32 (2005), pp. 1620-1631
[13.]
S. Cohen, E. Hurd, J. Cush, M. Schiff, M.E. Weinblatt, L.W. Moreland, et al.
Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin-1 receptor antagonist, in combination with methotrexate: Results of a twenty-four-week, multicenter, randomized, double-blind, placebo-controlled trial.
Arthritis Rheum, 46 (2002), pp. 614-624
[14.]
A.A. Fitzgerald, S.A. Leclercq, A. Yan, J.E. Homik, C.A. Dinarello.
Rapid responses to anakinra in patients with refractory adult-onset Still's disease.
Arthritis Rheum, 52 (2005), pp. 1794-1803
[15.]
C.A. Dinarello.
Blocking IL-1 in systemic inflammation.
J Exp Med, 201 (2005), pp. 1355-1359
[16.]
J.C. Edwards, L. Szczepanski, J. Szechinski, A. Filipowicz-Sosnowska, P. Emery, D.R. Close, et al.
Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis.
N Engl J Med, 350 (2004), pp. 2572-2581
[17.]
J.M. Kremer, M. Dougados, P. Emery, P. Durez, J. Sibilia, W. Shergy, et al.
Treatment of rheumatoid arthritis with the selective costimulation modulator abatacept: twelve-month results of a phase iib, double-blind, randomized, placebo-controlled trial.
Arthritis Rheum, 52 (2005), pp. 2263-2271
[18.]
J. Higashida, T. Wun, S. Schmidt, S.M. Naguwa, J.M. Tuscano.
Safety and efficacy of rituximab in patients with rheumatoid arthritis refractory to disease modifying antirheumatic drugs and anti-tumor necrosis factor-alpha treatment.
J Rheumatol, 32 (2005), pp. 2109-2115
[19.]
M.C. Genovese, J.C. Becker, M. Schiff, M. Luggen, Y. Sherrer, J. Kremer, et al.
Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition.
N Engl J Med, 353 (2005), pp. 1114-1123
[20.]
J. Esteve-Vives, E. Batlle-Gualda, A. Reig, Grupo para la Adaptación del HAQ a la Población Española.
Spanish version of the Health Assessment Questionnaire (HAQ): reliability, validity and transcultural equivalency.
J Rheumatol, 20 (1993), pp. 2116-2122
[21.]
E. Batlle-Gualda, I. Chalmeta Verdejo.
Calidad de vida en la artritis reumatoide.
Rev Esp Reumatol, (2002), pp. 9-21
[22.]
D.M. Van der Heijde, T. Dankert, F. Nieman, R. Rau, M. Boers.
Reliability and sensitivity to change of a simplification of the Sharp/van der Heijde radiological assessment in rheumatoid arthritis.
Rheumatology, 38 (1999), pp. 941-947
[23.]
M.L.L. Prevoo, M.A. Van’t Hof, H.H. Kuper, M.A. Van Leeuwen, B.A. Van de Putte, P.L.C.M. Van Riel.
Modified disease activity scores that include twenty-eight-joint counts.
Arthritis Rheum, 38 (1995), pp. 44-48
[24.]
M.A. Quinn, P.G. Conaghan, P. Emery.
The therapeutic approach of early intervention for rheumatoid arthritis: what is the evidence?.
Rheumatology, 40 (2001), pp. 1211-1220
[25.]
M. Boers.
Understanding the window of opportunity concept in early rheumatoid arthritis (review).
Arhritis Rheum, 48 (2003), pp. 1771-1774
[26.]
C. Grigor, H. Capell, A. Stirling, A.D. McMahon, P. Lock, R. Vallance, et al.
Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial.
[27.]
Y.P. Goekoop-Ruiterman, J.K. De Vries-Bouwstra, C.F. Allaart, D. Van Zeben, P.J.S.M. Kersten, J.M.W. Hazes, et al.
Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial.
Arthritis Rheum, 52 (2005), pp. 3381-3390
[28.]
J.S. Smolen, D.M. Van der Heijde, E.W. St.Clair, P. Emery, J.M. Bathon, E. Keystone, et al.
Predictors of joint damage in patients with early rheumatoid arthritis treated with high-dose methotrexate with or without concomitant infliximab.
Arthritis Rheum, 54 (2006), pp. 702-710
[29.]
O. Brocq, Y. Plubel, V. Breuil, C. Grisot, P. Flory, A. Mousnier, et al.
Etanercept - infliximab switch in rheumatoid arthritis 14 out of 131 patients treated with anti TNF. alpha.
Presse Med, 31 (2002), pp. 1836-1839
[30.]
K.E. Hansen, J.P. Hildebrand, M.C. Genovese, J.J. Cush, S. Patel, D.A. Cooley, et al.
The efficacy of switching from etanercept to infliximab in patients with rheumatoid arthritis.
J Rheumatol, 31 (2004), pp. 1098-1102
[31.]
R.F. Vollenhoven, E. Gullstrom, S. Brannemark, L. Klareskog.
Dose escalation of infliximab in clinical practice: Data from the Stockholm TNF registry.
Arthritis Rheum, 44 (2001), pp. S82
[32.]
O. Oniankitan, C. Duvoux, D. Challine, A. Mallat, X. Chevalier, J.M. Pawlotsky, et al.
Infliximab therapy for rheumatic diseases in patients with chronic hepatitis B or C.
J Rheumatol, 31 (2004), pp. 107-109
[33.]
M. Esteve, C. Saro, F. González-Huix, F. Suarez, M. Forne, J.M. Viver.
Chronic hepatitis B reactivation following infliximab therapy in Crohn's disease patients: need for primary prophylaxis.
Gut, 53 (2004), pp. 1363-1365
[34.]
J.R. Peterson, F.C. Hsu, P.A. Simkin, M.H. Wener.
Effect of tumor necrosis factor alpha antagonists on serum transaminases and viraemia in patients with rheumatoid arthritis and chronic hepatitis C infection.
Ann Rheum Dis, 62 (2003), pp. 1078-1082
[35.]
N.N. Zein.
Etanercept Study Group Etanercept as an adjuvant to interferon and ribavirin in treatment-naive patients with chronic hepatitis C virus infection: a phase 2 randomized, double-blind, placebo-controlled study.
J Hepatol, 42 (2005), pp. 315-322
[36.]
T. Ellerin, R.H. Rubin, M.E. Weinblatt.
Infections and anti-tumor necrosis factor therapy.
Arthritis Rheum, 48 (2003), pp. 3013-3022
[37.]
O. Elkayam, D. Caspi, T. Reitblatt, D. Charboneau, J.B. Rubins.
The effect of tumor necrosis factor blockade on the response to pneumococcal vaccination in patients with rheumatoid arthritis and ankylosing spondylitis.
Semin Arthritis Rheum, 33 (2004), pp. 283-288
[38.]
L. Carmona, J. Gómez Reino, R. González.
Registro español de acontecimientos adversos en enfermedades reumáticas (BIOBADASER). Informe de la situación a 14 Enero 2005.
Reumatol Clin, 1 (2005), pp. 95-111
[39.]
J. Listín, A. Strangfeld, S. Kary, R. Rau, U. Von Hinueber, M. Stoyanova-Scholz, et al.
Infections in patients with rheumatoid arthritis treated with biologic agents.
Arthritis Rheum, 52 (2005), pp. 3403-3412
[40.]
J. Keane, S. Gershon, R.P. Wise, E. Mirabil-Levens, J. Kasznica, W.D. Schwiterman, et al.
Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent.
N Engl J Med, 345 (2001), pp. 1098-1104
[41.]
J.J. Gomez-Reino, L. Carmona, V. Rodriguez-Valverde, E. Martin-Mola, C. Moreno, on behalf of the BIOBADASER Group, et al.
An active surveillance of rheumatoid arthritis patients treated with tumor necrosis factor inhibitors indicates significant tuberculosis risk increase.
Arthritis Rheum, 48 (2003), pp. 2122-2127
[42.]
Grupo de Trabajo sobre Tuberculosis.
Consenso nacional para el control de la tuberculosis en España.
Med Clin (Barc), 98 (1992), pp. 24-31
[43.]
Grupo de Trabajo del área TIR de SEPAR.
Recomendaciones SEPAR. Normativa sobre la prevención de la tuberculosis.
Arch Bronconeumol, 38 (2002), pp. 441-451
[44.]
American Thoracic Society.
Targeted tuberculin testing and treatment of latent tuberculosis infection.
Am J Respir Crit Care Med, 161 (2000), pp. S221-S247
[45.]
L. Carmona, J.J. Gomez-Reino, V. Rodriguez-Valverde, D. Montero, E. Pascual-Gomez, E.M. Mola, et al.
Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists.
Arthritis Rheum, 52 (2005), pp. 1766-1772
[46.]
R.S. Wallis, M.S. Broder, J.Y. Wong, M.E. Hanson, D.O. Beenhouwer.
Granulomatous infectious diseases associated with tumor necrosis factor antagonists.
Clin Infect Dis, 38 (2004), pp. 1261-1265
[47.]
N.R. Slifman, S.K. Gershon, J.H. Lee, E.T. Edwards, M.M. Braun.
Listeria monocytogenes infection as a complication of treatment with anti tumor necrosis factor α-neutralizing agents.
Arthritis Rheum, 48 (2003), pp. 319-324
[48.]
A. Warris, A. Bjorneklett, P. Gaustad.
Invasive pulmonary aspergillosis associated with infliximab therapy.
N Eng J Med, 344 (2001), pp. 1099-1100
[49.]
J.H. Lee, N.R. Slifman, S.K. Gherson, E.T. Edwards, W.D. Schwieterman, J.N. Siegel, et al.
Life-threatening histoplasmosis complicating immunotherapy with tumor nerosis factor α antagonists infliximab and etanercept.
Arthritis Rheum, 46 (2002), pp. 2565-2570
[50.]
L. Bergstrom, D.E. Yocum, J. Tesser, M. Miller, J.R. Lisse, O. Gluck.
Coccidiomycosis (valley fever) occurring during infliximab therapy.
Arthritis Rheum, 46 (2002), pp. S169
[51.]
B.E. Joven, A.J. Garcia Gonzalez, T. Ruiz, E. Moreno.
Pregnancy in women receiving anti-TNF-alpha therapy. Experience in Spain.
Arthritis Rheum, 49 (2005), pp. S884
[52.]
C.E. Antoni, D.E. Furst, B. Manger, G.R. Lichtenstein.
Outcome of pregnancy in women receiving infliximab for the treatment of Crohn's disease or rheumatoid arthritis.
Artrhitis Rheum, 44 (2001), pp. S152
[53.]
N. Mohan, E.T. Edwards, T.R. Cupps, P.J. Oliverio, G. Sanberg, H. Crayton, et al.
Demyelination occurring during anti-tumor necrosis factor a therapy for infflammatory arthritides.
Arthritis Rheum, 44 (2001), pp. 2862-2869
[54.]
F. Wolfe, K. Michaud.
Lymphoma in rheumatoid arthritis: the effect of methotrexate and anti-tumor necrosis factor therapy in 18,572 patients.
Arthritis Rheum, 50 (2004), pp. 1740-1751
[55.]
P. Geborek, A. Bladstrom, C. Turesson, A. Gulfe, I.F. Petersson, T. Saxne, et al.
Tumour necrosis factor blockers do not increase overall tumour risk in patients with rheumatoid arthritis, but may be associated with an increased risk of lymphomas.
Ann Rheum Dis, 64 (2005), pp. 699-703
[56.]
K.L. Hyrich, A.J. Silman, K.D. Watson, D.P. Symmons.
Anti-tumour necrosis factor alpha therapy in rheumatoid arthritis: an update on safety.
Ann Rheum Dis, 63 (2004), pp. 1538-1543
[57.]
E. Kimby.
Tolerability and safety of rituximab (MabThera).
Cancer Treat Rev, 31 (2005), pp. 456-473
Copyright © 2006. Elsevier España S.L. Barcelona
Idiomas
Reumatología Clínica

Suscríbase a la newsletter

Opciones de artículo
Herramientas
es en

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?